Animal Health Archives
02/20/2026
Biosecurity in Transit: How Veri-Clean® Protects Vaccines and Reproductive Materials
The outcomes of animal health vaccine programs, veterinary networks, and breeding operations depend on precision. Within these facilities, biosecurity protocols guide every action, and teams continuously monitor conditions. Everyone understands that dosage potency and genetic integrity hang in the balance, so nothing is left to chance. But the moment materials leave those walls, the equation changes.
02/18/2026
Build Standardization Where It Matters Most: Turning Stability into True Consistency
There is a quiet assumption that many early-phase teams make when they transition to cryopreserved starting material... that freezing alone will solve their variability problem. On the surface, it feels true. Cryopreservation stops the clock, stabilizes the cells, and removes the minute-to-minute fragility of fresh material. But the stability that teams expect isn’t guaranteed by freezing itself, it’s created by how the freezing is done. And in practice, this is where programs often get surprised.
01/27/2026
Preparing Animal Health Logistics for a More Regulated Future
Bringing an advanced animal health therapy to market today demands the same operational discipline once reserved for human biopharma. Yet animal health developers are still operating in an environment that lacks the robust logistics standards that govern human therapeutic transport. As programs expand across sites and geographies, the lack of shared and consistent handling expectations creates variability that becomes one of the biggest operational barriers to scale.
12/22/2025
Celebrating Innovation at the Cryoport Systems Grand Opening in Louvres, France
Cryoport Systems recently opened the doors of its newest Global Supply Chain Center (GSCC) in Louvres, France, marking a major step forward in how cell and gene therapies move safely and compliantly across Europe and the world. Strategically located just outside Paris and minutes from Charles de Gaulle Airport (CDG), this GSCC strengthens our integrated network and brings critical capabilities closer to sponsors, CROs, CDMOs, and clinical sites throughout the region, and strengthens our support of regional animal health and reproductive medicine organizations.
12/19/2025
Expert Q&A: Is Standardization the Bottleneck or Breakthrough to Building Scalable and Cost-Effective CGT Programs?
Cell and gene therapy (CGT) companies are under constant pressure to do more while hitting milestones earlier. Demonstrate manufacturability. Ensure regulatory readiness. Design for scalability and patient access. And do all of this with more constrained resources and increasingly aggressive timelines. Building on our recent panel discussion, we gathered extended perspectives from Dr. Don Fink (Dark Horse Consulting Group), Audrey Greenberg (Mayo Venture Partners), Dr. Dominic Clarke (Cryoport Systems), and Kurtis Carlisle (Cabaletta Bio).
12/17/2025
2025 Year in Review: Turning Standards and Resilience into Outcomes
If you work within the advanced therapy ecosystem, you already know the story of 2025 from an industry standpoint, where science continued accelerating while funding and commercialization hinged on whether the supporting systems could keep up. For Cryoport Systems, that reality was a catalyst. This year, we raised the bar yet again and demonstrated how having the right strategic partnership behind your end-to-end supply chain can turn logistics into leverage, can transform compliance into confidence, and can spin scale into speed.
12/17/2025
A Look Back at 2025 in Animal Health
Innovation is quickly outpacing regulation and driving the development of specialized medicine for the animal health industry. These advanced therapies and next-generation biologics are coming to market at a pace that demands precision and agility despite the lack of clear guidelines. In this complex environment, the dependability of your logistics strategy can determine future scalability and commercial success even before your product leaves the lab. The pre-clinical and initial trial phases are the ideal time to set the stage for growth, as building reliable, compliance-aligned processes early helps keep materials stable, data credible, and operations ready to evolve as your trials progress.
12/16/2025
Driving Compliance and Standardization in CGT Supply Chains
As cell and gene therapies (CGTs) continue to advance and more therapies reach late-stage clinical trials and commercialization, the complexity of the related logistics is only increasing. Therapies are crossing borders, reaching broader patient populations, and expanding into global distribution, all of which introduces risk if standards are inconsistent. Compliance and standardization, as a result, are essential for ensuring both scalability and patient safety.
12/15/2025
